| Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma BA Walker, EM Boyle, CP Wardell, A Murison, DB Begum, NM Dahir, ... Journal of clinical oncology 33 (33), 3911-3920, 2015 | 617 | 2015 |
| Early coagulopathy in trauma patients: an on-scene and hospital admission study B Floccard, L Rugeri, A Faure, M Saint Denis, EM Boyle, O Peguet, ... Injury 43 (1), 26-32, 2012 | 432 | 2012 |
| APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma BA Walker, CP Wardell, A Murison, EM Boyle, DB Begum, NM Dahir, ... Nature communications 6 (1), 6997, 2015 | 332 | 2015 |
| Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma T Facon, MA Dimopoulos, A Dispenzieri, JV Catalano, A Belch, M Cavo, ... Blood, The Journal of the American Society of Hematology 131 (3), 301-310, 2018 | 280 | 2018 |
| Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma C Herbaux, J Gauthier, P Brice, E Drumez, L Ysebaert, H Doyen, ... Blood, The Journal of the American Society of Hematology 129 (18), 2471-2478, 2017 | 244 | 2017 |
| Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients V Shah, AL Sherborne, BA Walker, DC Johnson, EM Boyle, S Ellis, ... Leukemia 32 (1), 102-110, 2018 | 233 | 2018 |
| Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II ‘proof-of-concept’iLOC study by the … C Soussain, S Choquet, M Blonski, D Leclercq, C Houillier, K Rezai, ... European journal of cancer 117, 121-130, 2019 | 224 | 2019 |
| Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients BA Walker, CP Wardell, A Brioli, E Boyle, MF Kaiser, DB Begum, NB Dahir, ... Blood cancer journal 4 (3), e191-e191, 2014 | 209 | 2014 |
| Management and outcome of primary CNS lymphoma in the modern era: an LOC network study C Houillier, C Soussain, H Ghesquières, P Soubeyran, O Chinot, ... Neurology 94 (10), e1027-e1039, 2020 | 150 | 2020 |
| A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial T Facon, MA Dimopoulos, N Meuleman, A Belch, M Mohty, WM Chen, ... Leukemia 34 (1), 224-233, 2020 | 149 | 2020 |
| Early human herpesvirus type 6 reactivation after allogeneic stem cell transplantation: a large-scale clinical study R Dulery, J Salleron, A Dewilde, J Rossignol, EM Boyle, J Gay, ... Biology of Blood and Marrow Transplantation 18 (7), 1080-1089, 2012 | 129 | 2012 |
| A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis M Roussel, G Merlini, S Chevret, B Arnulf, AM Stoppa, A Perrot, ... Blood, The Journal of the American Society of Hematology 135 (18), 1531-1540, 2020 | 126 | 2020 |
| Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitors L Tornatore, A Sandomenico, D Raimondo, C Low, A Rocci, ... Cancer Cell 26 (4), 495-508, 2014 | 126 | 2014 |
| Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia S Poulain, C Roumier, A Venet-Caillault, M Figeac, C Herbaux, G Marot, ... Clinical Cancer Research 22 (6), 1480-1488, 2016 | 118 | 2016 |
| The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma A Mikulasova, CP Wardell, A Murison, EM Boyle, GH Jackson, J Smetana, ... Haematologica 102 (9), 1617, 2017 | 104 | 2017 |
| The spectrum and clinical impact of epigenetic modifier mutations in myeloma C Pawlyn, MF Kaiser, C Heuck, L Melchor, CP Wardell, A Murison, ... Clinical cancer research 22 (23), 5783-5794, 2016 | 102 | 2016 |
| Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations C Pawlyn, L Melchor, A Murison, CP Wardell, A Brioli, EM Boyle, ... Blood, The Journal of the American Society of Hematology 125 (5), 831-840, 2015 | 98 | 2015 |
| Revealing the impact of structural variants in multiple myeloma EH Rustad, VD Yellapantula, D Glodzik, KH Maclachlan, B Diamond, ... Blood cancer discovery 1 (3), 258-273, 2020 | 90 | 2020 |
| MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome S Poulain, EM Boyle, C Roumier, H Demarquette, M Wemeau, S Geffroy, ... British journal of haematology 167 (4), 506-513, 2014 | 85 | 2014 |
| Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma T Dejoie, J Corre, H Caillon, C Hulin, A Perrot, D Caillot, E Boyle, ... Blood, The Journal of the American Society of Hematology 128 (25), 2941-2948, 2016 | 83 | 2016 |
